2012, № 12 (148)

1. Ermakova, N.A. Basic etiological factors and pathogenetic mechanisms of age-related macular degeneration development / N.A. Ermakova, O.Ts. Rabdanova // Clin. ophthalmology. — 2007. — Vol. 8, No. 3. — P. 125–128.

2. Ivanishko, Yu.A. "Classical" subfoveolar neovascular membranes: opportunities and prospects of treatment. Theses of reports. First Russian seminar "round table".– Rostov–on–don, 2004.– P. 96–103.

3. Bressler, N.M. Clinical characteristics of choroidal neovascular membranes / N.M. Bressler, S.B. Bressler, E.S. Gragoudas // Arch. Ophthalmol. — 1986. — Vol. 93. — P. 552-57.

4. Friedman, D.S. The Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States / D.S. Friedman, G.O'Colman, B. Munoz, S.C.Tomany, C. McCarty, P.T. de Jong // Arch. Ophthalmol. — 2004. –Vol. 122, №4. — P. 564–572.

5. Ferrara, N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis / N. Ferrara // Am. J. Phesiol. Cell Physiol. — 2001. — Vol. 280. — P. 1358–1366.

6. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. / Macular Photocoagulation Study Group. // Arch. Ophthalmol. — 1991. — Vol. 109, №8. — P. 1109–1114.

7. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial / Macular Photocoagulation Study Group // Arch. Ophthalmol. — 1990. –Vol. 108, №6. — P. 816–824.

About this article